Physician profile
Joanne C Lee
NPI 1457443657
$26,183.86
in general payments reported to CMS, 2019-2025
45 companies · $2,372 in 2025
The $2,372 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,966 · 2020: $3,937 · 2021: $3,302 · 2022: $2,926 · 2023: $3,729 · 2024: $3,951 · 2025: $2,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,052.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,305.46 | 2019-2025 | Jardiance |
| Amgen INC. | $3,470.13 | 2019-2025 | Repatha, Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $2,955.72 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Novo Nordisk INC | $1,430.78 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Sanofi-Aventis U.S. LLC | $1,211.74 | 2019-2025 | |
| Boston Scientific Corporation | $1,131.89 | 2019-2024 | Watchman Flx |
| Intuity Medical INC | $1,110.71 | 2022-2023 | Pogo Automatic Blood Glucose Monitoring System |
| Glaxosmithkline, LLC. | $745.09 | 2023-2025 | Arexvy, Shingrix |
| Esperion Therapeutics, INC. | $714.07 | 2021-2025 | Nexletol, Nexlizet |
| Abbott Laboratories | $601.84 | 2019-2025 | Supera, Freestyle Libre 3 |
| Lilly USA, LLC | $569.05 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Biohaven Pharmaceuticals, INC. | $530.39 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $471.61 | 2019-2023 | Verquvo |
| Mannkind Corporation | $455.38 | 2023-2024 | Afrezza, V-Go |
| Janssen Pharmaceuticals, INC | $441.67 | 2019 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanne Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.